238 related articles for article (PubMed ID: 27400739)
1. Characterization of the hepatic cytochrome P450 enzymes involved in the metabolism of 25I-NBOMe and 25I-NBOH.
Nielsen LM; Holm NB; Leth-Petersen S; Kristensen JL; Olsen L; Linnet K
Drug Test Anal; 2017 May; 9(5):671-679. PubMed ID: 27400739
[TBL] [Abstract][Full Text] [Related]
2. Identification of Metabolite Biomarkers of the Designer Hallucinogen 25I-NBOMe in Mouse Hepatic Microsomal Preparations and Human Urine Samples Associated with Clinical Intoxication.
Poklis JL; Dempsey SK; Liu K; Ritter JK; Wolf C; Zhang S; Poklis A
J Anal Toxicol; 2015 Oct; 39(8):607-16. PubMed ID: 26378134
[TBL] [Abstract][Full Text] [Related]
3. Studies on the metabolism and toxicological detection of the new psychoactive designer drug 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe) in human and rat urine using GC-MS, LC-MS(n), and LC-HR-MS/MS.
Caspar AT; Helfer AG; Michely JA; Auwärter V; Brandt SD; Meyer MR; Maurer HH
Anal Bioanal Chem; 2015 Sep; 407(22):6697-719. PubMed ID: 26108532
[TBL] [Abstract][Full Text] [Related]
4. 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOME): A Harmful Hallucinogen Review.
Kamińska K; Świt P; Malek K
J Anal Toxicol; 2021 Jan; 44(9):947-956. PubMed ID: 32128596
[TBL] [Abstract][Full Text] [Related]
5. 25C-NBOMe and 25I-NBOMe metabolite studies in human hepatocytes, in vivo mouse and human urine with high-resolution mass spectrometry.
Wohlfarth A; Roman M; Andersson M; Kugelberg FC; Diao X; Carlier J; Eriksson C; Wu X; Konradsson P; Josefsson M; Huestis MA; Kronstrand R
Drug Test Anal; 2017 May; 9(5):680-698. PubMed ID: 27448631
[TBL] [Abstract][Full Text] [Related]
6. Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT
Eshleman AJ; Wolfrum KM; Reed JF; Kim SO; Johnson RA; Janowsky A
Biochem Pharmacol; 2018 Dec; 158():27-34. PubMed ID: 30261175
[TBL] [Abstract][Full Text] [Related]
7. 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe): clinical case with unique confirmatory testing.
Stellpflug SJ; Kealey SE; Hegarty CB; Janis GC
J Med Toxicol; 2014 Mar; 10(1):45-50. PubMed ID: 23872917
[TBL] [Abstract][Full Text] [Related]
8. Retrospective Demonstration of 25I-NBOMe Acute Poisoning Using Hair Analysis.
Ameline A; Farrugia A; Raul JS; Kintz P
Curr Pharm Biotechnol; 2017; 18(10):786-790. PubMed ID: 29189143
[TBL] [Abstract][Full Text] [Related]
9. Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats.
Elmore JS; Decker AM; Sulima A; Rice KC; Partilla JS; Blough BE; Baumann MH
Neuropharmacology; 2018 Nov; 142():240-250. PubMed ID: 29501528
[TBL] [Abstract][Full Text] [Related]
10. Bad trip due to 25I-NBOMe: a case report from the EU project SPICE II plus.
Hermanns-Clausen M; Angerer V; Kithinji J; Grumann C; Auwärter V
Clin Toxicol (Phila); 2017 Sep; 55(8):922-924. PubMed ID: 28471280
[TBL] [Abstract][Full Text] [Related]
11. A retrospective analysis of the "Neverending Trip" after administration of a potent full agonist of 5-HT2A receptor - 25I-NBOMe.
Schetz D; Schetz A; Kocić I
Biomed Pharmacother; 2022 Feb; 146():112295. PubMed ID: 34980551
[TBL] [Abstract][Full Text] [Related]
12. Metabolic characterization of 25X-NBOH and 25X-NBOMe phenethylamines based on UHPLC-Q-Exactive Orbitrap MS in human liver microsomes.
Xiang J; Wen D; Zhai W; Zhao J; Xiang P; Ma C; Shi Y
J Pharm Biomed Anal; 2024 May; 242():116020. PubMed ID: 38359493
[TBL] [Abstract][Full Text] [Related]
13. Human cytochrome P450 kinetic studies on six N-2-methoxybenzyl (NBOMe)-derived new psychoactive substances using the substrate depletion approach.
Caspar AT; Meyer MR; Maurer HH
Toxicol Lett; 2018 Mar; 285():1-8. PubMed ID: 29277574
[TBL] [Abstract][Full Text] [Related]
14. Locomotor and discriminative stimulus effects of four novel hallucinogens in rodents.
Gatch MB; Dolan SB; Forster MJ
Behav Pharmacol; 2017 Aug; 28(5):375-385. PubMed ID: 28537942
[
